pancreatitis and glp-1 New data links agonists for weight loss with higher risk for pancreatitis, GI events Pancreatitis Risk Associated with GLP-1

The transdermal format allows gradual absorption throughout the day, making it ideal for busy schedules and consistent routine support

Discontinuation and reinitiation of dual-labeled glp-1 receptor agonists among us adults with overweight or obesity

The growing number of obese individuals due to several chronic disorders, changing lifestyle habits, rapid urbanization and digitalization fostering sedentary lifestyles

Vomiting occurred for 69 patients on 5mg, 106 patients on 10mg, and 132 patients on 15mg

GLP-1 agonists work by mimicking gut hormones that regulate appetite and blood sugar, slowing gastric emptying and increasing satiety signals in the brain

A federal panel has transferred three additional New Jersey lawsuits into the expanding multidistrict litigation accusing Eli Lilly and Novo Nordisk of downplaying serious side effects linked to popular GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Trulicity